• 1
    Goodkin DA, Young EW, Kurakawa K et al. Mortality among hemodialysis patients in Europe, Japan and the United States: case-mix effects. Am J Kidney Dis 2004; 44: 1621.
  • 2
    Kessler M, Zannad F, Lehert P et al. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant 2007; 22: 35739.
  • 3
    Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007; 11: 114.
  • 4
    Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 1995; 5: 107984.
  • 5
    Tripepi G, Mallamaci F, Zoccali C. Inflammation markers adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16(Suppl 1): S838.
  • 6
    Saran R, Bragg-Gresham JL, Levin NW et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 12228.
  • 7
    Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 220818.
  • 8
    Jardine AG, Fellström BC, Logan JO et al. Cardiovascular risk and renal transplantation: post hoc analysis of the Assessment of Lescol in Renal Transplantation (ALERT) study. Transplantation 2005; 46: 52936.
  • 9
    Couchoud C, Lebeeuw M, Moranne O et al. A clinical score to predict 6-month prognosis in elderly patients stating dialysis for end-stage renal disease. Nephrol Dial Transplant 2009; 24: 155361.
  • 10
    Cohen L, Ruthazer R, Moss AH, Germain MJ. Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol 2010; 5: 729.
  • 11
    Lindholm B, Davies S. A new comorbidity index for estimating mortality risk in ESRD. Nat Rev Nephrol 2010; 6: 3912.
  • 12
    Fellström BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395407.
  • 13
    Suki WN, Zabaneh R, Cangiano Jl et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 11307.
  • 14
    Fellström B, Zannad F, Schmieder R et al. Effect of rosuvastatin on outcomes in chronic hemodialysis patients- design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005; 6: 9.
  • 15
    Fellström B, Holdaas H, Jardine AG et al. Effect of rosuvastatin on outcomes in chronic hemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 2007; 30: 31422.
  • 16
    Lemeshow S, Hosmer SW. The use of goodness-of-fit statistics in the development of logistic regression models. Am J Epidemiol 1982; 115: 92106.